30 Day Trial

Anika Therapeutics 3Q17 Revenue +7% vs. 3Q16

Share:

Anika Therapeutics posted 3Q17 orthobiologic revenue of US $24.0MM, +7.0% vs. 3Q16, and year-to-date revenue of $68.7MM, +5.2% vs. the prior year.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.